Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDB3OK)

Drug Name

MLN-3126 Drug Info

Synonyms

CCR9 antagonist (oral, Crohn's disease), Millennium

Indication

Disease Entry	ICD 11	Status	REF
Sjogren syndrome	4A43.20	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C-C chemokine receptor type 9 (CCR9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vercirnon	DM6L5ZQ	Crohn disease	DD70	Phase 3	[3]
CCX-025	DMCWVS7	Crohn disease	DD70	Phase 1	[2]
CCX507	DMO7TES	Ulcerative colitis	DD71	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 9 (CCR9)	TTIPS8B	CCR9_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02209506) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants. U.S. National Institutes of Health.
2	Targeting T-cell migration in inflammatory bowel disease. J Intern Med. 2012 Nov;272(5):411-29.
3	GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs. 2010 Jul;13(7):472-81.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)